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Seizure semiologyEpilepsy often occurs in Rett syndrome and is considered a major problem. The aim of this study was to
deﬁne the clinical features of epilepsy and the correlation between seizures and both genotype and clinical
phenotype in the Rett population. One hundred sixty-ﬁve patients with Rett syndrome referred to four
Italian centers were recruited. All patients underwent video/EEG monitoring and molecular analysis of the
MECP2 gene or, in negative cases, of the CDKL5 and FOXG1 genes. The frequency of epilepsy was 79%. Drug-
resistant epilepsy occurred in 30% of all our patients with Rett syndrome and in 38% of those with epilepsy.
Our ﬁndings demonstrate that epilepsy differs among the various phenotypes and genotypes with respect to
age at onset, drug responsiveness, and seizure semiology. The Hanefeld and preserved speech variants
represent the extremes of the range of severity of epilepsy: the preserved speech variant is characterized by
the mildest epileptic phenotype as epilepsy is much less frequent, starts later, and is less drug resistant than
what is observed in the other phenotypes. Another important ﬁnding is that seizure onset before 1 year of
age and daily frequency are risk factors for drug resistance. Thus, this study should help clinicians provide
better clinical counseling to the families of patients with Rett syndrome.sychiatry, Istituto "G. Gaslini,"
03.
taudi).
l rights reserved.© 2010 Elsevier Inc. All rights reserved.1. Introduction
Rett syndrome (RS) is a rare neurodevelopmental disorder affecting
1/10,000 to 1/15,000 females [1]. The diagnosis of RS is based on clinical
characteristics, including an initial period of apparently normal
development (ages 6–12 months), followed by a period of rapid decline
with loss of hand use and spoken language and the onset of stereotypic
hand movements, abnormal gait, and growth failure. The clinical
spectrum varies from classic to variant forms, including formes frustes,
which are characterized by preserved ambulation or speech and early
onset or congenital presentation, with severe epilepsy [2]. In 1999,
MECP2 gene mutations on the X chromosome were found to be
associated with RS, and account for approximately 80% of cases [3, 4].
Recently, CDKL5 gene mutations have been identiﬁed in girls affected
by atypical RS with early-onset seizures [5]. A third gene, FOXg1, is
reported to be responsible for some congenital variant forms [6].Although epilepsy occurs in about 80% of patients with RS [7], and
despite being viewed both by families and by clinicians as a major
problem in RS [8], there has been little research into the features
of seizures and the correlation between genotype and epileptic
phenotype [7, 9–11]. Both the presence and the severity of epilepsy
have been correlated with low body mass index, early developmental
problems, poorer mobility, and greater clinical severity [9, 11]. The
effects of X-chromosome inactivation status and other epigenetic
inﬂuences on gene expression are now being investigated, and the
results suggest that one MECP2 target, that is, brain-derived neuro-
trophic factor (BDNF), plays a signiﬁcant role in determining seizure
severity in RS [12, 13].
The aim of this study was to deﬁne the clinical features of epilepsy
in RS: age at seizure onset, semiology of seizures, and correlation
between seizures and both genotype and clinical phenotype in the
Rett population.
2. Methods
This multicenter, retrospective study was carried out between
January 2008 and November 2009 at the Giannina Gaslini Children's
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been clinically diagnosed with Rett syndrome according to European
Society of Paedriatic Neurology criteria deﬁned in 2001; had to have
undergonemolecular analysis of theMECP2 gene or, in negative cases,
of the CDKL5 gene; and had to have undergone video/EEGmonitoring.
On the basis of these criteria, data for 165 subjects were collected
from a cohort of patients referred to four Italian child neuropsychiatry
departments: G. Gaslini Institute, University of Genoa; St. Paolo
Hospital, Milan; University Hospital, Siena; Spedali Civili, Brescia.
A questionnaire was made up in order to obtain longitudinal
data including clinical information on seizures, EEG ﬁndings, and
treatment. It was completed by one researcher, collecting data from
patients’ﬁles, hospital charts and from the physician in charge of the
patients. Phenotypes were categorized as follows: classic, congenital,
preserved speech variant (PSV), formes frustees (FF), and early-onset
seizure type (Hanefeld variant). The genotypes of cases with a
previously identiﬁed MECP2 mutation were categorized as late
truncating C-terminal deletions, large gene deletions, and T158M,
R255X, R270X, R306C, R168X, R294X, R133C, R106W, and P152R
mutations, and were then grouped into two categories: missense
mutations and truncating mutations. As the importance of the MeCP2
protein in terms of functionality is well known, we divided the
mutations into those involving (NLS+) and those not involving
(NLS–) the nuclear localization signal (NLS) (Table 1).Table 1
Characteristics of patients with Rett syndrome.
Characteristic All No epil
N 165 35 (21
Phenotype
Classic forms 140 (84.8)a 25 (18
Preserved speech variant 15 (9.1) 8 (53
Formes frustes 3 (1.8) 2 (67
Hanefeld variant 6 (3.6) —
Congenital variant 1 (0.6) —
Genotype
MECP2+ 147 (89.1) 30 (20
CDKL5+ 5 (3) —
FOXG1+ 1 (0.6) —
Negative on genetic investigation 12 (7.3) 5 (41
Mecp2 mutations
Late truncating C-terminal deletions 29 (19.7) 10 (34
Large deletions 10 (6.8) 1 (10
T158M 17 (11.6) 3 (17
R255X 16 (10.9) 2 (12
R270X 14 (9.5) 3 (21
R306C 14 (9.5) 2 (14
R168X 10 (6.8) 2 (20
R294X 9 (6.1) 1 (11
R133C 6 (4.1) 2 (33
R106W 6 (4.1) —
P152R 5 (3.4) 1 (20
Othersb 11 (7.5) 3 (27
Type of MECP2 mutation
Group 1c
Missense 54 10 (18
Truncating 54 9 (16
Group 2
NLS– 84 20 (23
NLS+ 63 10 (15
Microcephaly 96 (60.4) 17 (51
Age at epilepsy onset
Mean±SD 4.7±3.7 —
Median (range) 4 (0.1–21)
Age at last follow-up
Mean±SD 14.9±8.5 13.7±
Median (range) 14 (2–40) 14 (3–
a N (%).
b Includes one patient for each of the following mutations: E14fs, P251fs, P302L, Q297X
c Group 1 does not include late truncanting C-terminal deletions and large deletions.
d Drug-resistant epilepsy versus drug-responsive epilepsy, P=0.02.Seizures were classiﬁed according to criteria of the International
League Against Epilepsy [14]. We took into consideration seizure
semiology at onset and at last follow-up. Each subject was scored
with respect to frequency of seizures: 1=daily seizures, 2=weekly
seizures, 3=monthly or sporadic seizures, 4=absence of seizures. An
epileptic score was assigned to each patient: 1=no epileptic seizures,
2=drug-responsive epileptic seizures, 3=drug-resistant epileptic
seizures. Microcephaly was also taken into consideration as a
parameter in our investigation to identify the presence of a correlation
with epilepsy. Drug-resistant epilepsy was deﬁned as the failure of
two appropriate AEDs, the occurrence of an average of one or more
seizures per month for ≥18 months, and no longer than a 3-month
seizure-free hiatus during those 18 months [15].
The reasons for and methods of the study protocol were carefully
explained to the families of the patients, and informed consent was
obtained.
2.1. Statistical analysis
Data are described as means and SD or median and range for
continuous variables, and as absolute and relative frequencies for
categorical variables. Nonparametric analysis (Mann–Whitney U test)
for continuous variables and the Chi square or Fisher's exact test
for categorical variables were used to measure differences betweenepsy Drug-responsive epilepsy Drug-resistant epilepsy
.2) 81 (49.1) 49 (29.7)
) 73 (52) 42 (30)
.3) 5 (33.3) 2 (13.3)
) 1 (33) —
1 (17) 5 (83)
1 (100) —
.4) 75 (51) 42 (28.6)
1 (20) 4 (80)
1 (100) —
.7) 4 (33.3) 3 (25)
.5) 17 (58.6) 2 (6.9)
) 7 (70) 2 (20)
.6) 6 (35.3) 8 (47.1)
.5) 7 (43.8) 7 (43.8)
.4) 8 (57.1) 3 (21.4)
.3) 8 (57.1) 4 (28.6)
) 4 (40) 4 (40)
) 4 (44.5) 4 (44.5)
.3) 3 (50) 1 (16.7)
3 (50) 3 (50)
) 3 (60) 1 (20)
) 5 (46) 3 (27)
.5) 25 (46.3) 19 (35.1)
.6) 26 (48.2) 19 (35.1)
.8) 42 (50) 22 (26.2)
.9) 33 (52.3) 20 (31.7)
.5) 51 (65.4) 28 (58.3)
5.3±4.2 3.6±2.5d
4 (0.1–21) 3.2 (0.1–12)
10.4 15±7.9 16±8.2
37) 14 (2–37) 15 (3–40)
R111G, R306H, R453X, T322A, L124F, Y141X, D156E.
Fig. 1. Epileptic score versus phenotype. Epileptic score: 1=no epileptic seizures,
2=drug-responsive epileptic seizures, 3=drug-resistant epileptic seizures.
Table 2
Clinical risk factors for drug-resistant epilepsy: Univariate analysis.
Characteristic Drug-responsive
epilepsy
Drug-resistant
epilepsy
OR 95% CI P value
Age at epilepsy onset
N1 year 76 (95) 39 (81.3) Ref.
≤1 year 4 (5) 9 (18.8) 4.27 1.23–14 0.02
Microcephaly
No 27 (34.6) 20 (41.7)
Yes 51 (65.4) 28 (58.3) 0.74 0.35–1.55 0.43
Seizure semiology
Complex partial
seizures
36 (46.2) 20 (44.4) Ref.
Generalized
seizures
37 (47.4) 41 (51.1) 1.12 0.53–2.38
Both 5 (6.4) 2 (4.4) 0.72 0.13–4.06 0.87
Seizure frequency at onset
Monthly 23 (47.9) 5 (16.7) Ref.
Weekly 11 (22.9) 6 (20) 2.51 0.63–10
Daily 14 (29.2) 19 (63.3) 6.24 1.90–20 0.009
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all P values were based on two-tailed tests. Statistical analysis was
performed using SPSS for Windows (SPSS Inc., Chicago, IL, USA).
3. Results
The clinical features of our series of 165 patients are detailed in
Table 1. The median age at last follow up was 14 years (range: 2–40).
There were 140 (84.8%) patients with classic forms, 15 (9.1%) with
the PSV, 6 (3.6%) with the Hanefeld variant, 3 (1.8%) with formes
frustes, and 1 (0.6) with the congenital form. Eight patients with
classic forms were negative on genetic investigation and 132 were
found to carry an MECP2 mutation. Fourteen patients with the PSV
had amutation in theMECP2 gene. All patients with forma frusta were
negative on genetic investigation. Patients with the Hanefeld variant
included all ﬁve subjects with CDKL5 mutations and one subject with
a MECP2 mutation (R106W). The patient with the congenital form
had a mutation in the FOXG1 gene.
There were 130 (79%) patients with epilepsy in our cohort, and
their median age at last follow-up was 14.5 years (range: 2–40); 37
(28.5%) were ≥20 years of age. The median age at epilepsy onset
was 4 years (range: 1.5 months to 21 years). Seizures started after
10 years of age in 10 (7.7%) patients. Epileptic seizures always occurred
in those with the Hanefeld variant, whereas they occurred in 82%
of patients with classic forms but in only 46.7% of those with the
PSV (P=0.004). Patients with the PSV started having seizures later in
life than those with classic forms (6.1±4.3 years vs 4.8±3.6 years,
P=0.01).
With respect to genotype, all patients with CDKL5 mutations
started having seizures within the ﬁrst 12 months of life (0.45±
0.49 years), whereas the mean age at seizure onset was 4.7 years for
patients with an MECP2 mutation and 6.6 years for patients without
any identiﬁed mutation. Among our patients with MECP2 mutations,
we observed that subjects with large gene deletions started having
seizures later (6.72±7.14 years) than those with the other types
of mutations, particularly those with R168X and R255X mutations
(3.12±1.86 and 3.9±2.0 years, respectively).
There were no differences in age at seizure onset between those
with NLS+mutations and those with NLS–mutations (4.5±3.8 years
vs 4.9±3.5 years, P=0.46).
Patientswere subdivided into three groups on the basis of epileptic
score: patients without epileptic seizures (n=35, 21.2%), patients
with drug-responsive epileptic seizures (n=81, 49.1%), and patients
with drug-resistant epileptic seizures (n=49, 29.7%) (Table 1). There
were no signiﬁcant differences among the groups with respect to age
at last follow-up.
We observed that of the 37 patients who were ≥20 years of age,
25 (67.5%) were drug responsive and 12 (32.5%) were drug resistant,
whereas in the group b20 years of age, 56 (60%) subjects were drug
responsive. Eighty percent of patients with late-onset seizures (after
10 years of age) were drug responsive and had monthly or sporadic
seizures.
With respect to the correlation between epileptic score and clinical
phenotype, we found that drug-resistant epilepsy occurred signiﬁ-
cantly more often in those with the Hanefeld variant than in those
with classic forms (83% vs 30%, P=0.03). This difference was also
observed between patients with the Hanefeld variant and those with
the PSV (13%), but it did not reach statistical signiﬁcance, most likely
because of the small number of patients (Fig. 1). The mean age at
seizure onset differed signiﬁcantly between patients with drug-
responsive seizures (5.3±4.2 years) and those with drug-resistant
seizures (3.6±2.5 years, P=0.02).
Moreover, monthly or sporadic seizures started at an older age
as compared with daily seizures (5.8±5.3 years vs 3.1±2.2 years,
P=0.02). Thus, we observed that an age at epilepsy onset≤1 year and
daily frequency at onset represent risk factors for drug resistance inpatients with Rett syndrome with epilepsy (OR=4.27, 95% CI=1.23–
14, P=0.02; OR=6.24, 95% CI=1.90–20, P=0.009) (Table 2).
To statistically evaluate the correlation between epilepsy and
genotype, we could include only patients with nomutations and those
with the most frequently found mutations, that is, late truncating
C-terminal deletions, large gene deletions, and T158M, R255X,
R270X, R306C, R168X, and R294X mutations. Epilepsy occurred
more frequently in patients with large gene deletions (N=9/10, 90%)
and the R294X mutation (N=8/9, 89%), and less frequently in subjects
with no identiﬁed mutations (N=7/12, 58%) and C-terminal deletions
(N=19/29, 66%). Moreover, C-terminal deletions seem to be a pro-
tective factor compared with the other mutations with respect to
both the occurrence of epilepsy and drug resistance (OR=0.43, 95%
CI=0.16–1.13, P=0.054, and OR=0.16, 95% CI=0.02–0.78, P=0.02,
respectively). In particular, C-terminal deletions are a protective factor
for drug-resistant epilepsy as compared with the most frequent
mutations: R255X (OR=0.12, 95% CI=0.01–0.89, P=0.02); T158M
(OR=0.09, 95% CI=0.01–0.67, P=0.007), R294X (OR=0.12, 95%
CI=0.01–1.19, P=0.04).
Of the 52 patients known to have X inactivation, 33 had balanced X
inactivation. No signiﬁcant correlations were found with either the
presence or severity of epilepsy.
We observed that microcephaly was more frequent in patients
with classic forms (65%) than in those with the PSV and Hanefeld
variant (21.4 a d 33.3%, P=0.01). Microcephaly occurred more
frequently in patients carrying NLS+ mutations (80%) than in those
carrying NLS–mutations (51%) (P=0.001). No signiﬁcant correlation
Fig. 2. Generalized seizure semiology at onset.
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(P=0.33 and P=0.37, respectively).
Data concerning the semiology of seizures at onset were available
for 123 patients (Table 3). Complex partial seizures (CPS) occurred in
56 patients (45.5%), and generalized seizures (GS) in 60 subjects
(48.8%). Seven patients (5.7%) had both kinds of seizures: three
patients had CPS and generalized tonic–clonic seizures [GTCS], two
patients had CPS and atypical absences, one patient had CPS and
myoclonic seizures, and 1 patient had CPS and spasms). Among 56
patients with partial seizures, 30 (53%) had a secondary generalization.
Five patients had two kinds of generalized seizures: one had atypical
absences and spasms; one had GTCS and atypical absences; one had
atonic and tonic seizures; one had GTCS, atonic, and tonic seizures;
and one had atypical absences and tonic seizures. Generalized seizure
semiology is illustrated in Fig. 2.
Because of the peculiarity of the CDKL5 epileptic phenotype [5, 16–
20] we also studied it as a distinct category: seizures at onset were
generalized in two patients (onewith GTCS and onewith spasms) and
partial in two other cases (both with generalization), whereas one
patient had partial seizures and spasms. There were no signiﬁcant
differences in seizure semiology at onset between patients with
and those without the MECP2 mutation or among the patients with
different kinds of mutations.
As for drug responsiveness, there were no differences between
patients with partial and those with generalized seizures (64.3% vs
61.7%, respectively) at onset. At follow-up, seizure semiology was
known for 92 subjects (Table 3). Generalized seizure semiology
was similar to what it was at seizure onset. Among the patients
with CDKL5 mutations, two still had generalized seizures (one with
myoclonic seizures and the other with myoclonic seizures, spasms,
and GTCS), whereas spasms and partial seizures occurred in two
cases, and GTCS in another case.
Patients with the Hanefeld variantmore frequently presentedwith
spasms (50%) andmyoclonic seizures (25%) than those with the other
phenotypes (7% and 6%, respectively).
Partial seizures responded to drugs more frequently than gener-
alized seizures (65.2% vs 48.7%, respectively), but this difference was
not statistically signiﬁcant (P=0.22).
Physicians reported epileptic status in only 11 of our cases; however,
no additional data are available.
4. Discussion
In this study we analyzed the clinical features of epilepsy in RS,
particularly with respect to age at seizure onset, semiology of seizures,
and correlation with genotype and clinical phenotype. The frequency
of epilepsy among our cases was about 80%. This is in agreement
with data from the largest reports, such as the Australian study [7, 9].Table 3
Semiology of seizures.
Characteristic At onset
Complex partial seizures Generalized seizur
N 56 (45.5)a 60 (48.8)
Phenotype
Classic forms 50 (46.3) 53 (49.1)
Preserved speech variant 2 (28.6) 4 (57.1)
Formes frustes 1 (100)
Hanefeld variant 3 (50) 2 (33.3)
Congenital variant 1 (100)
Genotype
MECP2+ 50 (45.5) 55 (50)
CDKL5+ 2 (40) 2 (40)
FOXG1+ 1 (100)
Negative on genetic investigations 3 (42.9) 3 (42.9)
a N (%).Most seizures among our patients started between 2 and 5 years of
age. Only a very small percentage of our patients had seizure onset
after 10 years of age, and epilepsy was mild in most of these patients,
with sporadic frequency and drug-responsive seizures. We observed
similar percentages of partial and generalized seizures at onset, and
GTCS were the most frequent. At their last follow-up, most patients
were still having one kind of seizure, and GTCS were again the most
frequent, followed by atypical absences.
Our data show that semiology of seizures is not signiﬁcantly cor-
related with severity of epilepsy, even if generalized seizures would
appear to be more often associated with drug-resistant epilepsy, as
reported by Steffenburg et al. [21].
As the role of head circumference growth in association with
epilepsy is not clear [9], we investigated the correlation between
epilepsy and microcephaly and found that microcephaly is more
frequent in patients with classic forms than in those with the PSV or
Hanefeld variant. We also found that it is more frequent in patients
carrying NLS+ mutations than in those with NLS– mutations, but,
unlike Steffenburg et al. [21] and Moser et al. [22], we found no
correlation with either the presence or the severity of epilepsy. This
ﬁnding is similar to that reported by Glaze et al. in the American
cohort [11].
With respect to clinical phenotype, we found that the PSV is sig-
niﬁcantly correlated with a lower incidence of epilepsy than classic
forms. In people with the PSV, seizures start later and are drug
responsive inmost cases. Thus, epileptic features of the PSV aremilder
than classic phenotypes, as has been observed for various clinical
parameters reported by other authors [23, 24]. No differences were
found in seizure semiology among the clinical phenotypes at seizure
onset or at last follow-up, except for patients with the Hanefeld
variant, who more frequently had spasms and myoclonic seizures as
compared with patients with the other phenotypes.
In most cases (83%), the Hanefeld variant was associated with a
CDKL5mutation, and it has been conﬁrmed as being the formwith the
most severe epileptic phenotype [5, 16–20].
We found that mutations of the CDKL5 gene were always corre-
lated with early-onset epilepsy, and that all patients had seizures
within 12 months, whereas patients with no identiﬁed mutations hadAt follow-up
es Both Complex partial seizures Generalized seizures Both
7 (5.7) 24 (26.1) 39 (42.4) 29 (31.5)
5 (4.6) 22 (27.2) 34 (42) 25 (30.9)
1 (14.3) 3 (75%) 1 (25)
1 (100)
1 (16.7) 1 (16.7) 2 (33.3) 3 (50)
5 (4.5) 21 (26) 37 (46) 23 (28)
1 (20) — 2 (40) 3 (60)
— — —
1 (14.3) 3 (50) — 3 (50)
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started later. The latter point differs from what was reported by the
Australians [7], probably because our group of patients with no
mutations did not include any patients with CDKL5 mutations,
whereas the Australian study most likely did.
In patients with MECP2 mutations, C-terminal deletions proved
to be a protective factor as compared with the remaining Rett
population, with respect to both the occurrence of epilepsy and
drug resistance. At this point it is important to consider that a speciﬁc
BDNF polymorphism may inﬂuence epileptic phenotype and drug
responsiveness [12, 13]. Therefore, further genetic analysis is being
carried out in our patients.
Drug-resistant epilepsy occurred in 30% of all our patients with RS
and in 38% of those with RS with epilepsy. These data show a higher
percentage of drug resistance than what was reported by Buoni et al.
[25]. Nonetheless, they conﬁrm that most cases of Rett syndromewith
epilepsy are not drug resistant. Patients with drug-resistant epilepsy
start having seizures signiﬁcantly earlier than subjects with drug-
responsive epilepsy (3.6±2.5 years vs 5.3±4.2 years, P=0.02), and
their seizures are more frequent, often occurring daily.
We observed that both seizure onset before 1 year of age and
daily frequency are risk factors for drug resistance. Moreover, unlike
Steffenburg et al. [21], we observed no signiﬁcant differences in drug
responsiveness between patients with epilepsy ≥20 years of age and
younger subjects. This could mean that drug-resistant epilepsy often
continues, even at a later age.
In conclusion, epilepsy in Rett syndrome differs among the various
phenotypes and genotypes with respect to age at onset, drug respon-
siveness, and seizure semiology. CDKL5 mutations are always
correlated with early-onset epilepsy, which is drug resistant in most
cases. About 80% of patients with MECP2 mutations have seizures,
with a 28% rate of drug resistance. Patients with no identiﬁed
mutations have the lowest prevalence of epileptic seizures and the
latest onset. Taking into consideration the phenotypes, except for
the Hanefeld variant, which is associated with the highest frequency
of myoclonic seizures and spasms, we observed similar percentages
of cases having partial and generalized seizures in both patients
with classic forms and those with the PSV, with GTCS being the
most frequent type. Compared with the other phenotypes, the PSV
is characterized by mild epilepsy, that is, less frequent seizures, later
onset, and less drug resistance.
The most clinically relevant points of this study include the deﬁ-
nition of epileptic features for various phenotypes and genotypes
of Rett syndrome and the improvement of our prognostic knowledge
of epilepsy, thus providing the basis for clinical counseling for the
families of patients with Rett syndrome.References
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